Brought to you by 
Bayer, Aventis to form JV; deal terminated
01 Apr 2003
Executive Summary
Bayer and Aventis have signed a non-binding letter of intent to form a blood plasma joint venture that brings together their biological products businesses, Bayer Biological Products (protein discovery, purification, and processing) and Aventis's plasma protein subsidiary Aventis Behring.
Deal Industry
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Joint Venture
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bayer, Aventis to form JV; deal terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice